Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. more
Time Frame | GPCR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.62% | 0.31% | -1.26% |
1-Month Return | -18.13% | 0.6% | -4.16% |
3-Month Return | -30.69% | -9.44% | -0.46% |
6-Month Return | -42.99% | -5.15% | 3.58% |
1-Year Return | -43.39% | 0.33% | 22.47% |
3-Year Return | 69.2% | 4.53% | 25.13% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 20.03K | 266.35K | 623.26K | 949.17K | [{"date":"2020-12-31","value":2.11,"profit":true},{"date":"2021-12-31","value":28.06,"profit":true},{"date":"2022-12-31","value":65.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | (20.03K) | (266.35K) | (623.26K) | (949.17K) | [{"date":"2020-12-31","value":-2003400,"profit":false},{"date":"2021-12-31","value":-26635300,"profit":false},{"date":"2022-12-31","value":-62325800,"profit":false},{"date":"2023-12-31","value":-94917400,"profit":false}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 15.91K | 37.70K | 52.56M | 102.78M | [{"date":"2020-12-31","value":0.02,"profit":true},{"date":"2021-12-31","value":0.04,"profit":true},{"date":"2022-12-31","value":51.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (15.91K) | (37.70K) | (52.56M) | (102.78M) | [{"date":"2020-12-31","value":-1590600,"profit":false},{"date":"2021-12-31","value":-3769600,"profit":false},{"date":"2022-12-31","value":-5256100000,"profit":false},{"date":"2023-12-31","value":-10277500000,"profit":false}] | |
Total Non-Operating Income/Expense | 336.00 | (122.12K) | 2.51M | 26.78M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.46,"profit":false},{"date":"2022-12-31","value":9.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Pre-Tax Income | (15.74K) | (37.82K) | (51.30M) | (89.38M) | [{"date":"2020-12-31","value":-1573800,"profit":false},{"date":"2021-12-31","value":-3781800,"profit":false},{"date":"2022-12-31","value":-5130400000,"profit":false},{"date":"2023-12-31","value":-8938400000,"profit":false}] | |
Income Taxes | 138.00 | 231.00 | 17.00K | 236.00K | [{"date":"2020-12-31","value":0.06,"profit":true},{"date":"2021-12-31","value":0.1,"profit":true},{"date":"2022-12-31","value":7.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | (15.88K) | (38.05K) | (51.32M) | (89.62M) | [{"date":"2020-12-31","value":-1587600,"profit":false},{"date":"2021-12-31","value":-3804900,"profit":false},{"date":"2022-12-31","value":-5132100000,"profit":false},{"date":"2023-12-31","value":-8962000000,"profit":false}] | |
Income From Continuous Operations | (15.88K) | (38.05K) | (51.32M) | (89.62M) | [{"date":"2020-12-31","value":-1587600,"profit":false},{"date":"2021-12-31","value":-3804900,"profit":false},{"date":"2022-12-31","value":-5132100000,"profit":false},{"date":"2023-12-31","value":-8962000000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (15.88K) | (38.05K) | (51.32M) | (89.62M) | [{"date":"2020-12-31","value":-1587600,"profit":false},{"date":"2021-12-31","value":-3804900,"profit":false},{"date":"2022-12-31","value":-5132100000,"profit":false},{"date":"2023-12-31","value":-8962000000,"profit":false}] | |
EPS (Diluted) | - | - | (1.14) | (2.00) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-114,"profit":false},{"date":"2023-12-31","value":-200.16,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
GPCR | |
---|---|
Cash Ratio | 27.38 |
Current Ratio | 27.63 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GPCR | |
---|---|
ROA (LTM) | -13.01% |
ROE (LTM) | -17.69% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GPCR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GPCR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.61 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Structure Therapeutics Inc. American Depositary Shares (GPCR) share price today is $25.38
Yes, Indians can buy shares of Structure Therapeutics Inc. American Depositary Shares (GPCR) on Vested. To buy Structure Therapeutics Inc. American Depositary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GPCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Structure Therapeutics Inc. American Depositary Shares (GPCR) via the Vested app. You can start investing in Structure Therapeutics Inc. American Depositary Shares (GPCR) with a minimum investment of $1.
You can invest in shares of Structure Therapeutics Inc. American Depositary Shares (GPCR) via Vested in three simple steps:
The 52-week high price of Structure Therapeutics Inc. American Depositary Shares (GPCR) is $62.74. The 52-week low price of Structure Therapeutics Inc. American Depositary Shares (GPCR) is $23.5.
The price-to-earnings (P/E) ratio of Structure Therapeutics Inc. American Depositary Shares (GPCR) is
The price-to-book (P/B) ratio of Structure Therapeutics Inc. American Depositary Shares (GPCR) is 1.61
The dividend yield of Structure Therapeutics Inc. American Depositary Shares (GPCR) is 0.00%
The market capitalization of Structure Therapeutics Inc. American Depositary Shares (GPCR) is $1.45B
The stock symbol (or ticker) of Structure Therapeutics Inc. American Depositary Shares is GPCR